Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.

Ader, F; Bouscambert-Duchamp, M; Hites, M; Peiffer-Smadja, N; Poissy, J; Belhadi, D; Diallo, A; Lê, MP; Peytavin, G; Staub, T; Greil, R; Guedj, J; Paiva, JA; Costagliola, D; Yazdanpanah, Y; Burdet, C; Mentré, F.
Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14.
https://pubmed.ncbi.nlm.nih.gov/34534511/